The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children
Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and a...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2010-08, Vol.126 (2), p.256-262 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 262 |
|---|---|
| container_issue | 2 |
| container_start_page | 256 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 126 |
| creator | Simões, Eric A.F., MB, BS, DCH, MD Carbonell-Estrany, Xavier, MD, PhD Rieger, Christian H.L., MD Mitchell, Ian, MA, MB, ChB Fredrick, Linda, MS Groothuis, Jessie R., MD |
| description | Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants |
| doi_str_mv | 10.1016/j.jaci.2010.05.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_550198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674910008511</els_id><sourcerecordid>759317153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c673t-a45491d510d7746dc3d9f07f6a9e5316717e1db955ab1c86d23b8b47567dbdf53</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhi0EokvhD3BAljhwymI7sZ1IqFJV8SVV4kA5W4496TqbtRc72Sr8ehztUmgPnDz2PO_IM-8g9JqSNSVUvO_XvTZuzUh-IHxNmHiCVpQ0shA140_RipCGFkJWzRl6kVJP8r2sm-fojBHBKlHWK7S92QCGrgMz4tDhCGnvoh5DnHGavZlHpwd8cHFKOHicpjbBzwn8mEkzxbhEdxuAX87fYudxVu6dwdpb7IM_3czGDTajL9GzTg8JXp3Oc_Tj08ebqy_F9bfPX68urwsjZDkWuuJVQy2nxEpZCWtK23REdkI3wEsqJJVAbdtwrltqamFZ2dZtJbmQtrUdL89Rcayb7mA_tWof3U7HWQXt1OlpmyNQnBPa1Jm_OPI5swNrclNRDw9kDzPebdRtOChJmeCE5QLvTgViyNNJo9q5ZGAYtIcwJSV5U1JJeZnJt4_IPkzR52koyklVZ2PE8iF2pEwMKUXo7v9CiVqsV71arFeL9Ypwla3Pojf_dnEv-eN1Bj4cAcizPziIKhkH3oB12cxR2eD-X__ikdwMzjujhy3MkP72oRJTRH1flm_ZPZrXruaUlr8Byw7Xfg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504820668</pqid></control><display><type>article</type><title>The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SWEPUB Freely available online</source><creator>Simões, Eric A.F., MB, BS, DCH, MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda, MS ; Groothuis, Jessie R., MD</creator><creatorcontrib>Simões, Eric A.F., MB, BS, DCH, MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda, MS ; Groothuis, Jessie R., MD ; Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><description>Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age–matched controls. Results The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Conclusion Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2010.05.026</identifier><identifier>PMID: 20624638</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Age Factors ; Allergies ; Allergy and Immunology ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Asthma ; Asthma - etiology ; Asthma - prevention & control ; Child, Preschool ; Children & youth ; Disease Susceptibility ; Family medical history ; Female ; Follow-Up Studies ; Food allergies ; Food Hypersensitivity - etiology ; Food Hypersensitivity - prevention & control ; Humans ; Infant ; Infant, Newborn ; lower respiratory tract infection ; Male ; Palivizumab ; Prospective Studies ; recurrent wheezing ; Respiratory Sounds - drug effects ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - complications ; Respiratory Syncytial Virus Infections - drug therapy ; Respiratory Syncytial Viruses ; Respiratory Tract Infections - complications ; Respiratory Tract Infections - drug therapy ; Risk Factors</subject><ispartof>Journal of allergy and clinical immunology, 2010-08, Vol.126 (2), p.256-262</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2010 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 2010</rights><rights>Copyright © 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. 2010 American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c673t-a45491d510d7746dc3d9f07f6a9e5316717e1db955ab1c86d23b8b47567dbdf53</citedby><cites>FETCH-LOGICAL-c673t-a45491d510d7746dc3d9f07f6a9e5316717e1db955ab1c86d23b8b47567dbdf53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674910008511$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20624638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:121201321$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Simões, Eric A.F., MB, BS, DCH, MD</creatorcontrib><creatorcontrib>Carbonell-Estrany, Xavier, MD, PhD</creatorcontrib><creatorcontrib>Rieger, Christian H.L., MD</creatorcontrib><creatorcontrib>Mitchell, Ian, MA, MB, ChB</creatorcontrib><creatorcontrib>Fredrick, Linda, MS</creatorcontrib><creatorcontrib>Groothuis, Jessie R., MD</creatorcontrib><creatorcontrib>Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><title>The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age–matched controls. Results The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Conclusion Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.</description><subject>Age Factors</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Asthma</subject><subject>Asthma - etiology</subject><subject>Asthma - prevention & control</subject><subject>Child, Preschool</subject><subject>Children & youth</subject><subject>Disease Susceptibility</subject><subject>Family medical history</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Food allergies</subject><subject>Food Hypersensitivity - etiology</subject><subject>Food Hypersensitivity - prevention & control</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>lower respiratory tract infection</subject><subject>Male</subject><subject>Palivizumab</subject><subject>Prospective Studies</subject><subject>recurrent wheezing</subject><subject>Respiratory Sounds - drug effects</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - complications</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Respiratory Syncytial Viruses</subject><subject>Respiratory Tract Infections - complications</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Risk Factors</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kk1v1DAQhi0EokvhD3BAljhwymI7sZ1IqFJV8SVV4kA5W4496TqbtRc72Sr8ehztUmgPnDz2PO_IM-8g9JqSNSVUvO_XvTZuzUh-IHxNmHiCVpQ0shA140_RipCGFkJWzRl6kVJP8r2sm-fojBHBKlHWK7S92QCGrgMz4tDhCGnvoh5DnHGavZlHpwd8cHFKOHicpjbBzwn8mEkzxbhEdxuAX87fYudxVu6dwdpb7IM_3czGDTajL9GzTg8JXp3Oc_Tj08ebqy_F9bfPX68urwsjZDkWuuJVQy2nxEpZCWtK23REdkI3wEsqJJVAbdtwrltqamFZ2dZtJbmQtrUdL89Rcayb7mA_tWof3U7HWQXt1OlpmyNQnBPa1Jm_OPI5swNrclNRDw9kDzPebdRtOChJmeCE5QLvTgViyNNJo9q5ZGAYtIcwJSV5U1JJeZnJt4_IPkzR52koyklVZ2PE8iF2pEwMKUXo7v9CiVqsV71arFeL9Ypwla3Pojf_dnEv-eN1Bj4cAcizPziIKhkH3oB12cxR2eD-X__ikdwMzjujhy3MkP72oRJTRH1flm_ZPZrXruaUlr8Byw7Xfg</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Simões, Eric A.F., MB, BS, DCH, MD</creator><creator>Carbonell-Estrany, Xavier, MD, PhD</creator><creator>Rieger, Christian H.L., MD</creator><creator>Mitchell, Ian, MA, MB, ChB</creator><creator>Fredrick, Linda, MS</creator><creator>Groothuis, Jessie R., MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><general>American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U9</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20100801</creationdate><title>The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children</title><author>Simões, Eric A.F., MB, BS, DCH, MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda, MS ; Groothuis, Jessie R., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c673t-a45491d510d7746dc3d9f07f6a9e5316717e1db955ab1c86d23b8b47567dbdf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Age Factors</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Asthma</topic><topic>Asthma - etiology</topic><topic>Asthma - prevention & control</topic><topic>Child, Preschool</topic><topic>Children & youth</topic><topic>Disease Susceptibility</topic><topic>Family medical history</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Food allergies</topic><topic>Food Hypersensitivity - etiology</topic><topic>Food Hypersensitivity - prevention & control</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>lower respiratory tract infection</topic><topic>Male</topic><topic>Palivizumab</topic><topic>Prospective Studies</topic><topic>recurrent wheezing</topic><topic>Respiratory Sounds - drug effects</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - complications</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Respiratory Syncytial Viruses</topic><topic>Respiratory Tract Infections - complications</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simões, Eric A.F., MB, BS, DCH, MD</creatorcontrib><creatorcontrib>Carbonell-Estrany, Xavier, MD, PhD</creatorcontrib><creatorcontrib>Rieger, Christian H.L., MD</creatorcontrib><creatorcontrib>Mitchell, Ian, MA, MB, ChB</creatorcontrib><creatorcontrib>Fredrick, Linda, MS</creatorcontrib><creatorcontrib>Groothuis, Jessie R., MD</creatorcontrib><creatorcontrib>Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Virology and AIDS Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simões, Eric A.F., MB, BS, DCH, MD</au><au>Carbonell-Estrany, Xavier, MD, PhD</au><au>Rieger, Christian H.L., MD</au><au>Mitchell, Ian, MA, MB, ChB</au><au>Fredrick, Linda, MS</au><au>Groothuis, Jessie R., MD</au><aucorp>Palivizumab Long-Term Respiratory Outcomes Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2010-08-01</date><risdate>2010</risdate><volume>126</volume><issue>2</issue><spage>256</spage><epage>262</epage><pages>256-262</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age–matched controls. Results The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Conclusion Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>20624638</pmid><doi>10.1016/j.jaci.2010.05.026</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2010-08, Vol.126 (2), p.256-262 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_550198 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; SWEPUB Freely available online |
| subjects | Age Factors Allergies Allergy and Immunology Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Asthma Asthma - etiology Asthma - prevention & control Child, Preschool Children & youth Disease Susceptibility Family medical history Female Follow-Up Studies Food allergies Food Hypersensitivity - etiology Food Hypersensitivity - prevention & control Humans Infant Infant, Newborn lower respiratory tract infection Male Palivizumab Prospective Studies recurrent wheezing Respiratory Sounds - drug effects Respiratory syncytial virus Respiratory Syncytial Virus Infections - complications Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Viruses Respiratory Tract Infections - complications Respiratory Tract Infections - drug therapy Risk Factors |
| title | The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A33%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20respiratory%20syncytial%20virus%20on%20subsequent%20recurrent%20wheezing%20in%20atopic%20and%20nonatopic%20children&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Sim%C3%B5es,%20Eric%20A.F.,%20MB,%20BS,%20DCH,%20MD&rft.aucorp=Palivizumab%20Long-Term%20Respiratory%20Outcomes%20Study%20Group&rft.date=2010-08-01&rft.volume=126&rft.issue=2&rft.spage=256&rft.epage=262&rft.pages=256-262&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2010.05.026&rft_dat=%3Cproquest_swepu%3E759317153%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504820668&rft_id=info:pmid/20624638&rft_els_id=1_s2_0_S0091674910008511&rfr_iscdi=true |